ImQuest receives two-year grant to develop pyrimidinedione product as anti-HIV topical microbicide

Samjin Pharm says that its AIDS treatment co-developer successfully acquired funding from the National Institute of Allergy and Infectious Disease (NIAID/NIH) to support the development of pyrimidinedione inhibitors as topical microbicides to prevent the sexual transmission of HIV.

The two-year Small Business Innovative Research grant provides funding for the continued development of the dua...